The instruments, reagents, and software that power modern biological research are experiencing an unprecedented investment cycle as genomics, precision medicine, and AI-assisted drug discovery reshape the life sciences landscape. A new report from Kings Research finds the global life science tools market grew from USD 139.53 billion in 2023 to a projected USD 152.45 billion in 2024, with expectations to more than double to USD 309.59 billion by 2031, reflecting a compound annual growth rate of 10.65% across the forecast window. The projections illustrate how deeply embedded advanced research technology has become in both academic discovery and commercial drug development pipelines.

Life science tools encompass the full spectrum of instruments, technologies, reagents, and software used to study and analyze biological systems, spanning sequencing platforms, microscopy equipment, mass spectrometers, PCR machines, and laboratory reagents. These tools are indispensable across academic research, pharmaceutical development, biotechnology, and clinical diagnostics, enabling scientists to identify disease pathways, develop new treatments, and expand fundamental biological understanding.

Biotechnology Expansion and Chronic Disease Burden Drive Investment

The rapid worldwide growth of biotechnology research is a central force propelling the market forward, as biomanufacturing, synthetic biology, and genetic engineering increasingly depend on sophisticated tools to enable scientific breakthroughs. Compounding this momentum is the rising global prevalence of chronic disease. A September 2023 World Health Organization report found that cardiovascular disease remains the leading cause of death worldwide, responsible for 17.9 million fatalities annually, followed by cancer at 9.3 million deaths, chronic respiratory disease at 4.1 million, and diabetes, including related kidney disease, contributing to 2 million deaths each year. This disease burden is driving sustained demand for tools that enable early detection, accurate diagnostics, and effective therapeutic development, with research institutions and pharmaceutical companies increasingly using these technologies to develop precision treatments tailored to individual patient profiles.

Next-generation sequencing technology continues to be a particularly important growth driver, as its ability to deliver deeper insight into genetic mutations, diseases, and therapeutic responses fuels demand for more sophisticated sequencing platforms. In October 2024, Illumina introduced its MiSeq i100 Series of sequencing systems, designed to offer unmatched benchtop speed and simplicity, providing laboratories with an affordable, user-friendly, all-inclusive system that delivers valuable insights even for users with limited sequencing expertise.

AI Integration Accelerates Drug Discovery and Diagnostics

The integration of artificial intelligence and machine learning into laboratory workflows has emerged as a defining industry trend, enhancing both efficiency and analytical precision. In December 2024, researchers at MIT unveiled Boltz-1, an open-source AI model capable of matching the performance of Google's AlphaFold3 in predicting the three-dimensional structures of proteins and other biological molecules, marking a significant advance in accessible computational biology tools. That same month, a collaboration between POSTECH's Professor Sangmin Lee and 2024 Nobel Chemistry Laureate Professor David Baker of the University of Washington introduced a groundbreaking AI-powered therapeutic platform capable of replicating complex viral structures, opening new possibilities in gene therapeutics and next-generation vaccine development.

Academic institutions are contributing to this wave of innovation as well. In December 2024, researchers at the University of California, San Diego, introduced the Spatial Modeling Algorithms for Reactions and Transport software, a tool capable of accurately simulating cell-signaling networks and modeling how cells respond to environmental signals, with potential applications spanning systems biology, pharmacology, and biomedical engineering. Such developments reflect the growing establishment of academic and research institutions worldwide, which continue to generate significant demand for sophisticated laboratory tools and technologies.

Consumables Lead Product Segment, Genomics Dominates Technology Mix

By product category, consumables led the market in 2023, generating USD 66.17 billion in revenue. Reagents, chemicals, and laboratory kits remain integral to experiments, diagnostics, and ongoing research activity, ensuring consistent demand driven by their essential role in daily laboratory operations. Their comparatively lower cost relative to capital equipment, combined with the frequent need for replenishment, continues to support the segment's dominant position, further reinforced by the expanding adoption of personalized medicine and growing research activity in genomics and proteomics.

By technology, genomics secured the largest revenue share at 35.59% in 2023. Rising demand for precise, scalable DNA sequencing and analysis solutions has accelerated the adoption of genomic technologies, with continued advances in next-generation sequencing improving efficiency, cost-effectiveness, and accessibility across diagnostics, agriculture, and biotechnology applications. Ongoing innovation in CRISPR gene editing and bioinformatics is expected to further reinforce genomics' market leadership through the forecast period.

By end-user, biotechnology and pharmaceutical companies are projected to post the strongest growth, expanding at a CAGR of 12.31% through 2031. These organizations rely heavily on advanced life science tools to support drug discovery, clinical trials, and biologics manufacturing, with rising demand for precision medicine and personalized treatment further increasing the need for advanced genomic sequencing, protein analysis, and molecular diagnostic capabilities.

North America Leads, Asia-Pacific Set for Fastest Growth

North America accounted for approximately 36.74% of the global market in 2023, with a valuation of USD 51.26 billion. The region remains a global leader in biotechnology and pharmaceutical research, with increased investment in drug discovery, personalized medicine, and biologics driving demand for genomic sequencing, high-throughput screening, and mass spectrometry technologies. According to a 2024 report from the Pharmaceutical Research and Manufacturers of America, biopharmaceutical companies and their suppliers were operating 1,580 production facilities across 48 states and Puerto Rico by April 2023, with nearly 20% dedicated to manufacturing active pharmaceutical ingredients. Substantial government funding through bodies such as the National Institutes of Health in the U.S. and the Canadian Institutes of Health Research further reinforces the region's leadership position.

Asia-Pacific is expected to be the fastest-growing region, expanding at a CAGR of 11.70% and reaching a projected USD 67.94 billion by 2031. The region has emerged as a key hub for clinical trials given its large, genetically diverse patient populations and comparatively lower costs, while growing collaboration between global pharmaceutical companies and regional biotech firms continues to increase demand for advanced life science tools, particularly in genomics, oncology, and infectious disease research. Expanding investment in agricultural biotechnology across China and India, including crop genomics and pest-resistant crop development, is opening additional growth avenues for the region.

Competitive Landscape

Leading companies including Agilent Technologies, Becton Dickinson, F. Hoffmann-La Roche, DH Life Sciences, Illumina, Merck KGaA, Thermo Fisher Scientific, Bio-Rad Laboratories, Qiagen, and Bruker Corporation continue to compete through partnerships, acquisitions, and product innovation. In December 2024, Merck entered into a definitive agreement to acquire HUB Organoids Holding, a Netherlands-based leader in organoid technology, reinforcing the company's strategic focus on next-generation biology. That same month, Illumina introduced its MiSeq i100 Series, further extending the company's sequencing portfolio with a system designed to make next-generation sequencing more accessible to laboratories with varying levels of technical expertise.

Outlook

As biotechnology research accelerates, chronic disease burdens rise, and AI becomes increasingly embedded in scientific discovery, the life science tools market is positioned for sustained double-digit growth through 2031. Providers that can combine cutting-edge analytical precision with affordability and ease of use stand to capture the greatest share of this expanding global opportunity.